Newsroom

Drug pricing concerns? Not at Gilead

After drug pricing concerns weighed on Gilead Sciences’ stock toward the end of December, the drugmaker has kicked off 2015 the same way it did the previous two years: by increasing prices on several products.

Read more

Gilead Drops After Drug Manager Blocks $1,000 Hep C Pill

Gilead shares sank after the biggest drug-benefit manager in the U.S. chose a pill from AbbVie to be the sole hepatitis C treatment approved for many patients, as insurers seek to rein in the rising cost of medicine.

Read more

Gilead’s Dispute With Insurers Leaves Doctors on Sidelines

Doctors caught in the middle of an escalating battle over U.S. drug prices are losing influence over their patients’ treatment even as they gain an opportunity to treat more people more affordably.

Read more

Special Sale Price: Docs Divided Over Discount on AbbVie Hepatitis C Drug

The decision by Express Scripts to make the AbbVie hepatitis C treatment the exclusive option for patients with the most common type of the virus caused a ruckus on Wall Street, although the reaction among some doctors and patient advocates was mixed.

Read more